New York-based SK Capital Partners, which focuses on the specialty materials, ingredients, and life sciences sectors, has entered into exclusive negotiations with LISI Group to acquire LISI Group’s Medical division, through its affiliate.
The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, it is expected to close in the second half of 2025.
Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers.
The Company’s products include instruments utilised in minimally invasive and robotic-assisted surgery as well as orthopedic implants. Lisi Medical operates four manufacturing sites with expertise in precision machining, forging, and engineering solutions, including highly automated production – two in Minnesota, US and two in France.
Kirkland & Ellis is serving as legal counsel and Piper Sandler & Co, Jefferies, and Sycomore Corporate Finance are serving as financial advisors to SK Capital. Partners Group, acting on behalf of its clients, provided committed debt financing in support of the transaction.
Rothschild & Co is serving as financial advisor and Dentons is serving as legal counsel to LISI Group.
